Delphia Therapeutics

Delphia Therapeutics hired David Kerstein as Chief Medical Officer. Kerstein previously held the same role at IDRx and Theseus Pharmaceuticals, bringing deep pharma CMO experience.

Leadership read: Delphia Therapeutics has brought in a CMO who has held that exact role at two other oncology-focused biotechs, IDRx and Theseus Pharmaceuticals, both of which were built around precision-oncology platforms with significant clinical and regulatory complexity. That hiring profile commits Delphia to a clinical development posture, not a discovery one. A CMO with consecutive operating-CMO experience at asset-stage companies is typically the person who runs IND-to-proof-of-concept execution, manages investigator relationships, and owns the FDA dialogue. The bench they've added is oriented toward getting something into, and through, the clinic. The related signals available here are thin for this vertical: the 12 comparable signals in the last 90 days span real estate, entertainment, consulting, and media, with no meaningful oncology or biopharma cluster to anchor a pattern read. Taken on its own, the Delphia hire sits within a well-established dynamic in early-stage biotech: platforms that have secured enough capital to run clinical programs recruit operating CMOs before trial initiation, not after. Companies at this stage of clinical readiness in precision oncology consistently face demand for regulatory operations leadership alongside the CMO, particularly functions that bridge clinical design, biomarker strategy, and FDA engagement. The market is moving toward operators who can compress time-to-proof-of-concept without sacrificing the regulatory integrity that underpins partnering conversations.

curated · 2026-06-26 · context →